GLS

GLENMARK LIFE SCIENCES

Small Cap BSE: 543322 NSE: GLS
₹380.4
-2.65 (-0.69%)
As on 30 September, 2022 | 02:22

Glenmark Life Sciences Share Price

Glenmark Life Sciences Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in GLENMARK LIFE SCIENCES

Start SIP

Glenmark Life Sciences Share Returns

  • Over 1 Month -13.42%
  • Over 3 Month -13.64%
  • Over 6 Month -20.63%
  • Over 1 Year -43.65%

Glenmark Life Sciences Key Statistics

P/E Ratio 10.9
PEG Ratio
Market Cap Cr 4,661
Price to Book Ratio 2.3
EPS 34.2
Dividend 5.5
Relative Strength Index 13.34
Money Flow Index 26.27
MACD Signal -10.97
Average True Range 11.47

Glenmark Life Sciences Investment Rating

  • Master Rating:
  • Glenmark Life Sciences has an operating revenue of Rs. 2,088.19 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 27% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 5 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 151 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Glenmark Life Sciences Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 49051452256252547
Operating Expenses Qtr Cr 34337237639436430
Operating Profit Qtr Cr 14714214616716017
Depreciation Qtr Cr 1010101091
Interest Qtr Cr 0007212
Tax Qtr Cr 38393637344
Net Profit Qtr Cr 1099910411510110

Glenmark Life Sciences Technicals

EMA & SMA

Current Price
380.4
-2.65 (-0.69%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 412.91
  • 50 Day
  • 430.9
  • 100 Day
  • 449.61
  • 200 Day
  • 486.27
  • 20 Day
  • 419.39
  • 50 Day
  • 439.33
  • 100 Day
  • 442.39
  • 200 Day
  • 486.16

Glenmark Life Sciences Resistance and Support

PIVOT
₹381.02
Resistance
First Resistance 392.04
Second Resistance 401.02
Third Resistance 412.04
RSI 13.34
MFI 26.27
MACD Single Line -10.97
MACD -15.32
Support
First Resistance 372.04
Second Resistance 361.02
Third Resistance 352.04

Glenmark Life Sciences Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 112,720 6,971,732 61.85
Week 159,088 9,930,285 62.42
1 Month 145,475 10,304,014 70.83
6 Month 79,783 4,848,410 60.77

Glenmark Life Sciences Result Highlights

Glenmark Life Sciences Synopsis

NSE-Medical-Ethical Drugs

Glenmark Life Scienc belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 2123.21 Cr. and Equity Capital is Rs. 24.51 Cr. for the Year ended 31/03/2022. Glenmark Life Sciences Ltd. is a Public Limited Listed company incorporated on 23/06/2011 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L74900PN2011PLC139963 and registration number is 139963.
Market Cap 4,661
Sales 2,088
Shares in Float 2.08
No of funds 49
Yield 5.52
Book Value 2.27
U/D Vol ratio 0.4
LTDebt / Equity
Alpha -0.22
Beta 0.57

Glenmark Life Sciences

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 82.85%82.85%82.84%
Mutual Funds 0.71%0.5%0.32%
Foreign Portfolio Investors 7.58%8.12%8.32%
Financial Institutions/ Banks
Individual Investors 8.14%7.8%7.72%
Others 0.72%0.73%0.8%

Glenmark Life Sciences Management

Name Designation
Mr. Glenn Saldanha Chairman & Non-Exe.Director
Mr. Yasir Rawjee Managing Director & CEO
Mr. Sumantra Mitra Executive Director
Mr. V S Mani Non Executive Director
Mr. Sridhar Gorthi Independent Director
Mrs. Manju Agarwal Independent Director
Mr. Taruvai Laxminarayanan Easwar Independent Director
Ms. Gita Nayyar Independent Director

Glenmark Life Sciences Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Glenmark Life Sciences Corporate Action

Date Purpose Remarks
2022-08-04 Quarterly Results
2022-04-20 Audited Results & Final Dividend
2022-02-08 Quarterly Results
2021-11-10 Quarterly Results
Date Purpose Remarks
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend

Glenmark Life Sciences MF Shareholding

Name Amount(cr)
Quant Active Fund Growth 2857
Nippon India Nifty Smallcap 250 Index Fund Reg Gr 477
Motilal Oswal Nifty 500 Fund Regular Growth 348
Motilal Oswal Nifty Smallcap 250 Index Fund Regular Growth 344
ICICI Prudential Nifty Smallcap 250 Index Fund Regular Growth 59

Glenmark Life Sciences FAQs

What is Share Price of Glenmark Life Sciences ?

Glenmark Life Sciences share price is ₹380 As on 30 September, 2022 | 02:08

What is the Market Cap of Glenmark Life Sciences ?

The Market Cap of Glenmark Life Sciences is ₹4660.9 Cr As on 30 September, 2022 | 02:08

What is the P/E ratio of Glenmark Life Sciences ?

The P/E ratio of Glenmark Life Sciences is 10.9 As on 30 September, 2022 | 02:08

What is the PB ratio of Glenmark Life Sciences ?

The PB ratio of Glenmark Life Sciences is 2.3 As on 30 September, 2022 | 02:08

Q1FY23